|
02 Aug 2021 |
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
|
|
02 Aug 2021 |
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
|
|
31 Jul 2021 |
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
|
|
30 Jul 2021 |
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
|
|
30 Jul 2021 |
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
|
|
28 Jul 2021 |
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
|
|
28 Jul 2021 |
Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose
|
|
23 Jul 2021 |
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union
|
|
23 Jul 2021 |
Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern
|
|
21 Jul 2021 |
EMA starts rolling review of COVID-19 vaccine Vidprevtyn
|
|
20 Jul 2021 |
OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
|
|
20 Jul 2021 |
Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose
|
|
20 Jul 2021 |
U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine
|
|
17 Jul 2021 |
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
|
|
13 Jul 2021 |
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
|
|
13 Jul 2021 |
Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
|
|
13 Jul 2021 |
ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate
|
|
09 Jul 2021 |
Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate
|
|
08 Jul 2021 |
Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor
|
|
07 Jul 2021 |
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
|
|
07 Jul 2021 |
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
|
|
04 Jul 2021 |
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
|
|
02 Jul 2021 |
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
|
|
02 Jul 2021 |
HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine
|
|
01 Jul 2021 |
Zydus applies to the DCGI for EUA to launch ZyCoV-D, the world’s first Plasmid DNA vaccine for COVID-19
|
